Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | NPY2R | P49146 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29974053 | 1.00 | TSHR (0.49) | TSHRGAACHRM1CHRM5CHRM2 | |
| SCHEMBL653593 | 1.00 | TSHR (0.49) | TSHRGAACHRM1CHRM5CHRM2 | |
| SCHEMBL15498509 | 0.93 | CHRM1 (0.50) | TSHRGAACHRM1CHRM5CHRM2 | |
| SCHEMBL8147886 | 0.88 | CYP2D6 (0.43) | TSHRCHRM1CHRM5CHRM2CYP3A4 | |
| SCHEMBL19467730 | 0.85 | CCR5 (0.42) | CHRM1CHRM5CHRM2ALDH1A1KDM4E | |
| SCHEMBL3582255 | 0.85 | CCR5 (0.42) | CHRM1CHRM5CHRM2ALDH1A1KDM4E | |
| SCHEMBL3575935 | 0.85 | CCR5 (0.42) | CHRM1CHRM5CHRM2ALDH1A1KDM4E | |
| SCHEMBL7687290 | 0.85 | CCR5 (0.42) | CHRM1CHRM5CHRM2ALDH1A1KDM4E | |
| SCHEMBL5130929 | 0.85 | CCR5 (0.42) | CHRM1CHRM5CHRM2ALDH1A1KDM4E | |
| SCHEMBL650351 | 0.85 | GPR119 (0.51) | ALDH1A1KDM4ENPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399468-B2 | Octahydro-pyrrolo[3,4-B]pyrrole derivatives | ABBOTT LABORATORIES (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120208820-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | SCHRIMPF MICHAEL R (US) | 2012-08-16 | — | — | US | disclosed |
| US-8119635-B2 | Diazabicyclic central nervous system active agents | ABBOTT LABORATORIES (US) | 2012-02-21 | — | — | US | disclosed |
| US-8026240-B2 | Octahydro-pyrrolo[3,4-b]pyrrole N-oxides | ABBOTT LABORATORIES (US) | 2011-09-27 | — | — | US | disclosed |
| EP-2316836-A1 | Substituted diazabicycloalkane derivatives as ligands at alpha 7 nicotinic acetylcholine receptors | Abbott Laboratories (US) | 2011-05-04 | — | — | EP | disclosed |
| EP-2298775-A1 | Diazabicyclic central nervous system active agents | Abbott Laboratories (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2295437-A1 | Diazabicyclic central nervous system active agents | Abbott Laboratories (US) | 2011-03-16 | — | — | EP | disclosed |
| US-7872010-B2 | Substituted diazabicycloalkane derivatives having affinity for nicotinic acetylcholine receptors | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | disclosed |
| US-20100222358-A1 | OCTAHYDRO-PYRROLO[3,4-B]PYRROLE DERIVATIVES | ABBOTT LABORATORIES (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100144700-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | TARGACEPT, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20090105267-A1 | OCTAHYDRO-PYRROLO[3,4-B]PYRROLE N-OXIDES | ABBOTT LABORATORIES (US) | 2009-04-23 | — | — | US | disclosed |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | US | disclosed |
| WO-2008112734-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | TARGACEPT, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| US-7399765-B2 | Substituted diazabicycloalkane derivatives | ABBOTT LABORATORIES (US) | 2008-07-15 | — | — | US | disclosed |
| US-20080097094-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2008-04-24 | — | — | US | disclosed |
| US-7319106-B2 | Diazabicyclic central nervous system active agents | ABBOTT LABORATORIES (US) | 2008-01-15 | — | — | US | disclosed |
| US-20070232612-A1 | Octahydro-pyrrolo[3,4-b]pyrrole Derivatives | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | ABBVIE INC. | 2005-05-12 | — | — | US | disclosed |
| US-6809105-B2 | (CIS)-6-(3-PYRIDINYL)-3,6-DIAZABICYCLO(3.2.0) HEPTANE FOR EXAMPLE; ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, ATTENTION DEFICIT HYPERACTIVITY DISORDER, DEPRESSION, NICOTINIC WITHDRAWAL SYNDROME, TOURETTE'S SYNDROME, AND SCHIZOPHRENIA | ABBOTT LABORATORIES | 2004-10-26 | — | — | US | disclosed |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080097094-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | GAP43, GABRE, CHRNA6 | TSHR 2636/4885GAA 1896/4885CHRM1 121/4885 |
| US-20100222358-A1 | OCTAHYDRO-PYRROLO[3,4-B]PYRROLE DERIVATIVES | HRH4, HRH2, TAC3 | TSHR 477/4885GAA 2612/4885CHRM1 969/4885 |
| US-20090105267-A1 | OCTAHYDRO-PYRROLO[3,4-B]PYRROLE N-OXIDES | TACR1, HTR3A, OPRM1 | TSHR 792/4885GAA 2772/4885CHRM1 300/4885 |
| US-20070232612-A1 | Octahydro-pyrrolo[3,4-b]pyrrole Derivatives | HRH4, HRH2, TAC3 | TSHR 446/4885GAA 2591/4885CHRM1 1044/4885 |
| US-20120208820-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | GAP43, GABRE, CHRNA6 | TSHR 2636/4885GAA 1896/4885CHRM1 121/4885 |
| US-20100144700-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | CHRNA10, CHRNA2, CHRNE | TSHR 428/4885GAA 3960/4885CHRM1 20/4885 |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | CHRNA7, CHRNA1, CHRNA2 | TSHR 741/4885GAA 2608/4885CHRM1 28/4885 |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | TSHR 2729/4885GAA 2018/4885CHRM1 77/4885 |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | CHRNA7, CHRNA2, CHRNA6 | TSHR 1509/4885GAA 648/4885CHRM1 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.